Astellas and CoMentis Enter into Deal for Novel Alzheimer's Drug
By The PharmaDeals Team
Pharma Deals Review: Vol 2008 Issue 94 (Table of Contents)
Published: 24 Apr-2008
DOI: 10.3833/pdr.v2008.i94.192 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Astellas has entered into a deal to build up its CNS pipeline by licensing CoMentis’ beta-secretase inhibitor programme for Alzheimer's disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS